Prevail Therapeutics
- Company typePrivate
- Founded2019
- HeadquartersNew York, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Prevail Therapeutics firmographics
Firmographics- Name
- Prevail Therapeutics
- Legal name
- Prevail Therapeutics Inc.
- Website
- https://prevailtherapeutics.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Prevail Therapeutics industry classification
Industry- Product category
- Gene Therapy / Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AAV Vector Gene Therapy Developers (HLAAACAA)
- akta.pro secondary industries
- Neurology/CNS Gene Therapies (HLAAACAH), siRNA Therapeutics (gene silencing) (HLAAADAB), Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
Keywords
Where Prevail Therapeutics is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Prevail Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Gene Therapy Commercialization: Once clinical trials are completed and regulatory approvals are obtained, Prevail expects to generate revenue through commercialization of gene therapies for Parkinson's disease and Gaucher disease. The company operates as a wholly owned subsidiary of Eli Lilly and Company, which provides commercial infrastructure for eventual product launch.
- Partnership Milestone Payments: Prevail receives milestone payments from collaboration partners such as Scribe Therapeutics for achievement of development, regulatory, and commercial milestones, plus royalties on future sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Prevail Therapeutics product offering
Product offeringCore offering
Prevail Therapeutics is a biotechnology company developing gene therapies and siRNA therapies that target the underlying genetic causes of neurodegenerative and rare diseases. Its pipeline includes AAV-based gene therapies for Parkinson's disease with GBA1 variants and Type 1 Gaucher disease, plus an siRNA therapy for sporadic Parkinson's disease, currently administered through three active clinical trial programs (PROPEL, PROCEED, PROSPECT).
Product overview
Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is developing three distinct clinical-stage genetic therapies targeting the root causes of neurodegenerative and rare diseases: PROPEL (gene therapy for Parkinson's disease with GBA1 variants, delivered via cisterna magna injection), PROCEED (gene therapy for Type 1 Gaucher disease, administered as a single intravenous infusion), and PROSPECT (siRNA therapy for sporadic Parkinson's disease, delivered via intrathecal injection). The company focuses on gene therapy and siRNA approaches that address underlying genetic causes rather than symptom management alone.
Differentiator
Problem solved
Functional benefit
Products and services
- PROPEL
Quantifiable outcome
- Clinical trials are evaluating safety, tolerability, and effectiveness of gene therapies designed to slow disease progression in Parkinson's and Gaucher disease patients
Companies that use Prevail Therapeutics
Customer profileSegments3 records
Ideal customer profiles3 records
Prevail Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Prevail Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Scribe TherapeuticscoreScribe Therapeutics and Prevail Therapeutics entered a strategic collaboration to develop in vivo CRISPR-based genetic medicines for neurological and neuromuscular diseases. Under the deal terms, Scribe receives $75 million upfront plus equity investment, with potential milestone payments exceeding $1.5 billion and tiered royalties on future sales. Scribe also retains the option to co-fund and share profits on one collaboration program in the United States. The collaboration focuses on leveraging Scribe's X-Editor (XE) CRISPR technology for in vivo genome editing in the CNS.
Scale indicators3 records
Recent moves5 records
Expansion highlights4 records
Prevail Therapeutics competitors and assessment
Company assessmentDirect peers
- uniQure: Gene therapy company developing AAV-based therapies with CNS programs including Huntington's disease. Highly comparable as a clinical-stage AAV developer focused on neurodegenerative rare diseases with similar regulatory pathway and manufacturing constraints.
- Sarepta Therapeutics: Commercial-stage gene therapy company with multiple approved AAV-delivered therapies and active pipeline in rare neurological diseases. Comparable as a fellow AAV gene therapy developer with operational scale in CNS and rare disease markets.
- REGENXBIO: AAV gene therapy platform company with CNS pipeline including Parkinson's disease programs. Comparable as a peer AAV developer pursuing neurodegenerative indications with proprietary delivery technology.
- Alnylam Pharmaceuticals: Leading siRNA therapeutics company with approved products and active CNS-pipeline development. Comparable for Prevail's PROSPECT program targeting α-synuclein in Parkinson's disease via siRNA approach.
- Voyager Therapeutics: Clinical-stage AAV gene therapy company focused on CNS/neurological diseases including Parkinson's disease programs. Most direct competitor to Prevail with overlapping AAV delivery approaches and Parkinson's disease as a lead indication.
Broad incumbents
- Roche/Genentech: Global pharmaceutical incumbent with significant gene therapy capabilities (including Spark Therapeutics) and active neurodegenerative disease programs. Comparable as a broad incumbent with overlapping CNS and gene therapy ambitions.
- Pfizer (Gene Therapy): Large pharmaceutical incumbent with a gene therapy division and CNS pipeline. Comparable as a broad incumbent pursuing AAV gene therapy for rare neurological diseases through a wider portfolio approach.
- Novartis (Gene Therapy): Global pharmaceutical incumbent with approved gene therapies (Zolgensma, Kymriah) and active CNS programs. Comparable as a broad incumbent with established gene therapy commercialization infrastructure.
- BioMarin Pharmaceutical: Specialty biopharmaceutical company with gene therapy programs targeting CNS diseases including Parkinson's. Comparable as an incumbent with overlapping AAV gene therapy ambitions in neurodegenerative rare diseases.
Emerging players
- Scribe Therapeutics: CRISPR-based in vivo genome editing company and Prevail's strategic partner. Comparable as a peer in CRISPR gene editing for neurological diseases via the X-Editor platform collaboration.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
Prevail Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prevail Therapeutics leadership team
Management profileNumber of profiles
Profiles4 records
Prevail Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prevail Therapeutics M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prevail Therapeutics
What does Prevail Therapeutics do?
Prevail Therapeutics is a biotechnology company developing gene therapies and siRNA therapies that target the underlying genetic causes of neurodegenerative and rare diseases. Its pipeline includes AAV-based gene therapies for Parkinson's disease with GBA1 variants and Type 1 Gaucher disease, plus an siRNA therapy for sporadic Parkinson's disease, currently administered through three active clinical trial programs (PROPEL, PROCEED, PROSPECT).
Is Prevail Therapeutics a public or private company?
Prevail Therapeutics is a private company. It is classified as corporate owned and is currently operating.
When was Prevail Therapeutics founded?
Prevail Therapeutics was founded in 2019. It employs 51 to 100 people.
Where is Prevail Therapeutics based?
Prevail Therapeutics is headquartered in New York, United States, in the North America region.
How does Prevail Therapeutics make money?
Two revenue lines are on record. Gene Therapy Commercialization is the primary driver. The others are partnership Milestone Payments.
Who are Prevail Therapeutics's main competitors?
Direct peers on record are uniQure, Sarepta Therapeutics, REGENXBIO, Alnylam Pharmaceuticals and Voyager Therapeutics. Broad incumbents are Roche/Genentech, Pfizer (Gene Therapy), Novartis (Gene Therapy) and BioMarin Pharmaceutical. Scribe Therapeutics is listed as an emerging player.
Does Prevail Therapeutics have an API?
No public API is recorded for Prevail Therapeutics.
What industry is Prevail Therapeutics in?
Prevail Therapeutics's product category is Gene Therapy / Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 541714 and its SIC code is 2834.